Company intelligence · Nasdaq: NAMS

NewAmsterdam Pharma: pipeline and clinical trials

NewAmsterdam Pharma is a biotech company built around a single drug, obicetrapib, an oral CETP inhibitor approved in the EU in September 2026. Its 9,541-patient PREVAIL outcomes trial is the company's defining pending event.

Legal name (SEC)NewAmsterdam Pharma Co N.V.
ListingNasdaq: NAMS
HeadquartersNaarden, the Netherlands
SEC filingsEDGAR (CIK 1936258)
Focus areasCardiovascular disease (LDL cholesterol), Alzheimer's disease (exploratory)

Key points

  • NewAmsterdam's pipeline centers on obicetrapib, alone and in a fixed-dose combination with ezetimibe.
  • The European Commission approved Ubeslo (obicetrapib) and Evlarco (obicetrapib/ezetimibe) on September 21, 2026, according to the company. Its partner in Europe is the Menarini Group.
  • openFDA lists no U.S. approval for obicetrapib.
  • PREVAIL, its cardiovascular outcomes trial, enrolled 9,541 patients; the registry lists an estimated primary completion in November 2026.
  • As a single-asset company, NewAmsterdam's outlook depends heavily on one trial result.

Tracked drug profiles

Drugs from this company that Spectral Genomics profiles in depth, with registry data and sourced analysis.

Active clinical trials

ClinicalTrials.gov lists 6 active trials with NewAmsterdam Pharma as lead sponsor (recruiting, not yet recruiting, active, or enrolling by invitation), retrieved Nov 19, 2026. Counts include only trials whose lead sponsor is registered as "NewAmsterdam Pharma".

By phase

Phase 23
Phase 33

Most common conditions

  • Lipidemia (2)
  • Atherosclerotic Cardiovascular Disease (1)
  • Coronary Artery Disease (1)
  • Plaque, Atherosclerotic (1)
  • Dyslipidemias (1)
  • Antioxidant Absorption (1)
  • Metabolic Syndrome (MetS) (1)
  • Type 2 Diabetes (T2DM) (1)

Conditions as registered by the sponsor; one trial can list several.

Largest active Phase 3 trials

TrialEnrollmentPrimary completion
PREVAIL · NCT05202509
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
9,541Nov 2026
REMBRANDT · NCT06305559
A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
300Nov 2027
RUBENS · NCT07219602
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
300Mar 2028

See this sponsor’s trials on ClinicalTrials.gov

A single-asset company

The registry lists six active NewAmsterdam trials, all of obicetrapib. They include PREVAIL, two coronary plaque imaging studies (REMBRANDT and RUBENS), and Phase 2 work in Alzheimer's disease. Companies built on one drug carry concentrated risk: a single trial result can redefine the company's prospects.

The CETP question

Obicetrapib belongs to a drug class with a difficult history. Torcetrapib increased deaths, dalcetrapib and evacetrapib showed no benefit, and anacetrapib produced a modest reduction in coronary events. The obicetrapib profile explains why the company positions it as an LDL-lowering drug, and why PREVAIL is the decisive test.

What to watch

  • PREVAIL results. The registry estimates primary completion in November 2026, and estimated dates often move.
  • Any U.S. regulatory plans, which the company's EU approval announcement did not describe.

Partnerships and corporate events

  • Menarini Group: European partner for Ubeslo and Evlarco, named in the company's EU approval announcement. Company-reported

Recent milestones

  1. Feb 7, 2022PREVAIL cardiovascular outcomes trial begins. Registry
  2. May 7, 2025BROADWAY Phase 3 results published: LDL −29.9% versus +2.7% with placebo. Peer-reviewed
  3. Jul 24, 2026EMA's CHMP adopts a positive opinion for Ubeslo and Evlarco. Company-reported
  4. Sep 21, 2026European Commission approves Ubeslo and Evlarco. Company-reported

Sources

  1. SEC EDGAR: NewAmsterdam Pharma Co N.V. filings (CIK 1936258).Regulator
  2. NewAmsterdam Pharma. European Commission approval for Ubeslo and Evlarco (September 21, 2026).Company-reported
  3. Nicholls SJ, et al. Safety and efficacy of obicetrapib in patients at high cardiovascular risk. New England Journal of Medicine. 2025;393(1):51–61.Peer-reviewed
  4. ClinicalTrials.gov. PREVAIL (NCT05202509).Registry
  5. ClinicalTrials.gov: active trials with this lead sponsorRegistry

This page is for education and research. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Company-reported information is labeled. See our disclaimer.